PRIMA‐1 and its structural analog, APR‐246, which are p53 reactivators, prevent mutant p53 aggregation and reverse the resulting amyloid state in cancer cells.[256] In addition, the peptides ReACp53, polyarginine, and its analogs halt p53 mutant amyloid formation and rescue p53 inhibition in cancer cells.[257, 258] The highly disordered steroid receptor coactivator 1 (SRC1) colocalizes with YAP‐transcriptional enhancer factor domain family member (TEAD) in phase‐separated transcriptional condensates. Here, PRIMA1 is linked to cancer.